May2026– 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation ...
Morning Overview on MSN
A targeted pill and a custom mRNA vaccine are both beating back pancreatic cancer in early trials — cracking open one of medicine’s hardest tumors
Pancreatic ductal adenocarcinoma has a five-year survival rate of roughly 13 percent, according to the American Cancer ...
Clinical Supply Agreement to support phase II clinical trial: Cambridge, UK Friday, May 22, 2026, 18:00 Hrs [IST] 4basebio PLC, a company pioneering an enzymatically ...
Oncology focused biotech to utilise 4basebio’s opDNA® technology to support Phase II clinical trial of immunotherapy candidate Multi-year, ...
Engage Bio’s Tethosome platform is designed to improve the potency, tolerability, and redosability of non-viral DNAAcquisition combines Engage’s innovative platform with Lilly’s broad genetic ...
RNA is the means of translating the genetic code embedded in DNA into proteins, which serve as enzymes, transporters, ...
The deal is Lilly's seventh acquisition of 2026 and centers on Engage's non-viral DNA delivery platform, Tethosome ...
Transaction terms include an undisclosed upfront cash payment plus development milestones, for up to $202 million total consideration, with no additional financial details disclosed. Engage’s ...
Targeted extended circulation LNP incorporating DARPins achieved complete B cell depletion in nonhuman primates through highly specific in vivo CD8+ T cell engineeringRobust study quantifies ...
Pharmaceutical Technology on MSN
Eli Lilly maintains M&A streak with $202m Engage Bio buyout
Lilly’s takeover of Engage Bio marks the seventh acquisition for the big pharma since the start of 2026.
A new AI-based system combines genomic sequences and RNA-binding protein profiles to model complex RNA splicing patterns ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results